AIM
SMMT icon

Aigen Investment Management’s Summit Therapeutics SMMT Stock Holding History

Aigen Investment Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$357K Buy
+24,477
New +$434K 0.1% 267
2024
Q4 		– Sell
-13,963
Closed -$306K – 975
2024
Q3 		$306K Buy
+13,963
New +$195K 0.06% 464

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Aigen Investment Management's SMMT Position: Q2 2026 in Review

Aigen Investment Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 24,477 shares worth $357K. The stake represents 0.1% of the portfolio and ranks #267 among its holdings. This is a return to the name: Aigen Investment Management previously reported a position in SMMT as recently as Q3 2024.

Aigen Investment Management first reported a position in SMMT in Q3 2024 and has held it in 2 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Aigen Investment Management held 24,477 shares of Summit Therapeutics worth $357K as of Q2 2026.
  • Summit Therapeutics was a new Aigen Investment Management position in Q2 2026.
  • Summit Therapeutics made up 0.1% of Aigen Investment Management's portfolio in Q2 2026, its #267 holding.
  • Aigen Investment Management first reported a position in Summit Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.